Aurinia Pharmaceuticals (AUPH) said Tuesday that an experimental medicine for dry-eye syndrome proved to be more effective but slightly less tolerable than Restasis, the best-selling treatment marketed by Allergan (AGN).

The Aurinia dry-eye drug is called VOS, and the reported clinical trial results were basically the opposite of what the company expected. Technically, the VOS study failed on tolerability — the primary goal.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Hi Adam….big fan of yours….high school education from Greece….restaurant business…..I try to understand things but it is hard especially in biotech….just a simple question….are you still kinda positive on aurinia….?…it is fine if you do not answer to this question for any reason….I know how busy you are…..god bless.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy